Ouargla

Researchers are conducting a prospective, multicenter, observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information about lung cancer patients in Algeria. The study focuses on understanding the epidemiological, clinical, pathological, molecular, and treatment characteristics of adults diagnosed with lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. This research aims to fill gaps in real-world data on lung cancer management and outcomes across Algeria's public healthcare system. The study involves collecting data during routine clinical care at 21 public and university hospitals specialized in oncology and pulmonology. Eligible adults, diagnosed at inclusion or within the prior 12 months, have their demographic information, tumor histology, molecular profiles, staging, and treatment details recorded in a secure electronic case report form. Treatments include surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, but no additional study-specific procedures or visits are required. Participants' medical history, risk factors, treatment responses, and adverse events are monitored through standard care over at least 12 months. The study measures key outcomes such as tumor characteristics at diagnosis, treatment modalities, progression-free survival, treatment discontinuation time, and overall survival. This large-scale registry, enrolling around 1,500 patients yearly over 30 months, aims to support national health planning and improve lung cancer care in Algeria.